Artiva Biotherapeutics Surges on Trading Debut
Cell Therapy Developer Artiva Refiles for a $100M IPO
Truist Financial Maintains Affimed NV(AFMD.US) With Buy Rating, Announces Target Price $25
Truist Financial analyst Srikripa Devarakonda maintains $Affimed NV(AFMD.US)$ with a buy rating, and sets the target price at $25.According to TipRanks data, the analyst has a success rate of 0.0% and
Affimed Price Target Raised to $25.00/Share From $15.00 by Laidlaw & Co.
Affimed Price Target Raised to $25.00/Share From $15.00 by Laidlaw & Co.
Affimed Is Maintained at Buy by Laidlaw & Co.
Affimed Is Maintained at Buy by Laidlaw & Co.
Truist Financial Maintains Affimed NV(AFMD.US) With Buy Rating
Truist Financial analyst Srikripa Devarakonda maintains $Affimed NV(AFMD.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 48.9% and a total average return of 5.5% o
Laidlaw Initiates Affimed NV(AFMD.US) With Buy Rating, Announces Target Price $25
Laidlaw analyst Yale Jen initiates coverage on $Affimed NV(AFMD.US)$ with a buy rating, and sets the target price at $25.According to TipRanks data, the analyst has a success rate of 29.7% and a total
H.C. Wainwright Maintains Affimed NV(AFMD.US) With Buy Rating, Maintains Target Price $10
H.C. Wainwright analyst Swayampakula Ramakanth maintains $Affimed NV(AFMD.US)$ with a buy rating, and maintains the target price at $10.According to TipRanks data, the analyst has a success rate of 36
Express News | HC Wainwright & Co. Reiterates Buy on Affimed, Maintains $10 Price Target
Affimed Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/13/2024 43.06% HC Wainwright & Co. $10 → $10 Reiterates Buy → Buy 06/03/2024 43.06% HC Wainwright & Co.
Affimed Says 86% of Patients Responded to Lymphoma Therapy in Mid-stage Trial
Affimed NV | 6-K: Report of foreign private issuer (related to financial reporting)
Affimed Reports Q1 Results
Express News | Affimed Anticipates Cash, Equivalents And Short-Term Investments To Support Operations Into H2 2025
Affimed Q1 EPS $(1.38) Beats $(1.54) Estimate, Sales $168.34K Miss $1.34M Estimate
Affimed (NASDAQ:AFMD) reported quarterly losses of $(1.38) per share which beat the analyst consensus estimate of $(1.54) by 10.44 percent. This is a 37.3 percent increase over losses of $(2.20) per s
Affimed 1Q Rev EUR155,000 >AFMD
Affimed 1Q Rev EUR155,000 >AFMD
Press Release: Affimed Reports First Quarter 2024 Financial Results & Business Update
Affimed Reports First Quarter 2024 Financial Results & Business Update - Initial data from the LuminICE-203 study shows 85.7% overall response rate (ORR) (6 of 7 patients); 4 out of 7 patients with c
Notable Earnings Before Wednesday's Open
Catalyst Watch: Apple's WWDC, Tesla's Annual Meeting, Fed's Dot Plot, and GameStop Volatility
Affimed NV | 6-K/A: Report of foreign private issuer (related to financial reporting)